Aloha Re: NMPS
For microcaps that mostly fly under the radar, it is easy to dwindle, pricewise - and NMPS has done that.
Today, it got favorable mention in Wall Street Journal, as a company that may get a serum based prostate cancer marker to trial/market, next year (in competition with Correlogic, who also work on serum cancer markers - but not the same as NMPS').
Favorable mention, of course, brings it back on the radar, for a while. Whether it can succeed in staying on radars, until a serum based prostate- (or colon- or breast cancer-) marker maa be ready, remains to be seen.
If NMPS can't, then today was a flash in a pan. If NMPS can, one analyst put a target price on this stock, a year ago, at $20...
If you want to play it, know that microcaps are somewhat more reliable than pennystocks, but they're still risky.
Be further adviced that patience is needed for microcaps. There can be half years between news of any significant content...
For a biotech microcap, the one thing that speaks in NMPS' favor, is that it already has some modest revenue from one cancer screen on the market. And whereas that's not enough to keep them in financial balance, it does contribute to it and the product keeps doing better each quarter.
If NMPS could hit success with one of it's three blood based cancer screens under development (they're working, as I mentioned, on breast, colon and prostate cancer tests from simple blood samples), then you can be fairly sure of a 10 fold return at the current price (and also more than that, IMO).
If they fail, they'll slowly waste away and you could loose all, if you hold on...
Disclosure: I do not currently hold shares in it, but I keep a close watch on it and may buy, one day...
KD
